Cancer Lectures

 

Assessing causality among super and exceptional responders

AACR 2020 lecture by Vinay Prasad MD MPH

Original date: June 22, 2020

Lecture 1 - Lay of the Land - Reading and Interpreting Cancer Trials Series

How to read and interpret cancer medicine in the broader context by Vinay Prasad MD MPH

Original Date: 05/05/2021

Lecture 2 - Surrogate Endpoints in Oncology - Reading and Interpreting Cancer Trials

How do we measure cancers? What are surrogate endpoints? What is progression-free survival?

Original Date: 05/05/2021

Lecture 2 - Surrogate Endpoints in Oncology - Reading and Interpreting Cancer Trials

How do we measure cancers? What are surrogate endpoints? What is progression-free survival?

Original Date: 05/05/2021

Lecture 3 - FDA Drug Approval 101- Reading and Interpreting Cancer Trials Series

Explore the terminology and drugs approved based on progression-free survival, overall survival, and response rate

Original Date: 5/11/2020

Super responders in the broader precision oncology landscape

AACR 2020 lecture Vinay Prasad MD MPH

Original Date: 6/22/2020

The Problem With the Evidence in Cancer Medicine

Lecture delivered to Equator conference

Original Date: February 2020

Grand rounds Alaska - A Deeper Drive in How To Keep Up and Be a Better Reader of the Literature

As astute listener point out that this is a better distribution for enalapril use at baseline

https://twitter.com/gbrlrgrs/status/1284450823897063424/photo/1

I agree! I think my point remains valid, that a fraction of people have a capped dose, and this population could tolerate a higher dose.

Old Fashioned Intelligence in Cancer Medicine

“The reason IBM Watson can win on Jeapordy, but won’t solve cancer, is that we know the answers to Jeapordy.” - Vinay Prasad, MD, MPH

Powell K, Prasad V. Old-fashioned Intelligence Will Always Be Needed in Medicine. As Part of a Debate. European Urology Focus. 2021

The ADAURA study/ Osimertinib: How Cheerleaders Fail Patients

Episode 2.55: ADAURA [38:01]